FDA drug approval bonanza sees cancer and orphan drugs on top again.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Changing R&D models in research-based pharmaceutical companies
Journal of Translational Medicine Open Access 27 April 2016
-
Repurposing medicinal compounds for blood cancer treatment
Annals of Hematology Open Access 07 June 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Mullard, A. 2012 FDA drug approvals. Nat Rev Drug Discov 12, 87–90 (2013). https://doi.org/10.1038/nrd3946
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3946
This article is cited by
-
Construction strategies for developing expression vectors for recombinant monoclonal antibody production in CHO cells
Molecular Biology Reports (2018)
-
Changing R&D models in research-based pharmaceutical companies
Journal of Translational Medicine (2016)
-
Debate: Molecular cardiac imaging is ready for the prime time con between wishful thinking and reality
Journal of Nuclear Cardiology (2016)
-
Pharmacokinetics of enzalutamide, an anti-prostate cancer drug, in rats
Archives of Pharmacal Research (2015)
-
Repurposing medicinal compounds for blood cancer treatment
Annals of Hematology (2015)